



ANUH PHARMA LTD.

Registered Office : 3-A, Shivsagar Estate, North Wing,
Dr. Annie Besant Road, Worli, MUMBAI - 400 018, INDIA.
Tel. : +91-22-6622 7575 • Fax : +91-22-6622 7600 / 7500
E-Mail : anuh@sk1932.com • CIN: L24230MH1960PLC011586

Date: 11th August, 2023

To,
The Manager (Listing)
ESE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Fort, Mumbai - 400 001

Ref: Scrip Code No. 506260

Sub: Submission of Unaudited Financial Results for the quarter ended June 30, 2023 along with Limited Review Report.

Please find enclosed herewith the **copy of newspaper advertisement** with respect to the Unaudited Financial Results and Limited review Report for the quarter ended June 30, 2023, published in the Financial Express and Mumbai Lakshadeep in compliance with **Regulation 47** of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly acknowledge the receipt and take the same on record.

Thanking you,

Yours faithfully

For Anuh Pharma Limited

Hemant Auti
Company Secretary & Compliance Officer



Encl as Above



Factory : E-17/3, E-17/4 & E-18, M.I.D.C., Tarapur, BOISAR, Dist. Paighar - 401 506, INDIA. Tel.: +91-7410055574 / 75

Independent Auditor's Review Report on the Quarterly Unaudited Financial Results of Anuh Pharma Limited (the "Company") Pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

**TO THE BOARD OF DIRECTORS
Anuh Pharma Limited**

1. We have reviewed the accompanying statement of unaudited financial results of Anuh Pharma Limited (the "Company") for the quarter ended 30th June, 2023 (the "Statement") attached herewith, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").
2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, (Ind AS 34) "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement of unaudited financial results, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013 as amended, read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For JAYANTILAL THAKKAR & CO.
CHARTERED ACCOUNTANTS
(FIRM REG. NO. 104133W)**



Vishal

**VISHAL D. SHAH
PARTNER
MEMBERSHIP NO. 123337
UDIN: 23123337BGQBMS4239**

**PLACE: Mumbai
DATE: 11th August, 2023**

ANUH PHARMA LTD.

CIN: L24230MH1960PLC011586

Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018

Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30th JUNE, 2023

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/06/2023	3 months ended 31/03/2023	3 months ended 30/06/2022	12 months ended 31/03/2023
		Unaudited	Audited -(Refer Note No.3)	Unaudited	Audited (Refer Note No.3)
(1)	(2)	(3)	(4)	(5)	(6)
I.	Revenue from operations	16,148.06	15,730.98	11,637.65	52,748.60
II.	Other income	346.97	103.72	95.50	611.45
III.	Total Revenue (I + II)	16,495.03	15,834.70	11,733.15	53,360.05
IV.	Expenses:				
	Cost of materials consumed	12,706.22	12,254.36	8,738.05	37,701.31
	Purchases of Stock-in-Trade	241.98	105.57	701.97	1,098.85
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(32.85)	(153.63)	(607.58)	1,348.08
	Employee benefits expense	477.17	434.93	425.92	1,715.09
	Finance costs	2.24	2.34	5.98	21.84
	Depreciation and amortization expense	200.87	240.74	241.75	970.02
	Other expenses	1,358.02	1,666.39	1,260.83	5,757.82
	Total expenses (IV)	14,953.65	14,550.70	10,766.92	48,613.01
V.	Profit / (Loss) before exceptional and items and tax (III - IV)	1,541.38	1,284.00	966.23	4,747.04
VI.	Exceptional items	-	-	-	-
VII.	Profit / (Loss) before tax (V - VI)	1,541.38	1,284.00	966.23	4,747.04
VIII.	Tax expenses:				
	(1) Current tax	366.00	381.00	246.00	1,212.00
	(2) Deferred tax	0.10	(59.30)	(13.30)	(82.92)
	Total Tax expenses (VIII)	366.10	321.70	232.70	1,129.08
IX.	Profit/(Loss) after Tax (VII-VIII)	1,175.28	962.30	733.53	3,617.96
X.	Other Comprehensive Income (net of Tax)				
	(i) Items that will not be reclassified to profit or loss	(3.15)	11.16	1.70	3.86
	(ii) Items that will be reclassified to profit or loss	-	-	-	-
	Total Other Comprehensive Income (net of Tax) (X)	(3.15)	11.16	1.70	3.86
XI.	Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)	1,172.13	973.46	735.23	3,621.82
	Paid up Equity Share Capital (Face value ₹ 5/- each)	2,505.60	2,505.60	2,505.60	2,505.60
	Other Equity (excluding revaluation reserves)				21,616.54
XII.	Earnings per equity share (For respective periods) (In Rs.)				
	(1) Basic	2.35	1.92	1.46	7.22
	(2) Diluted	2.35	1.92	1.46	7.22

See accompanying notes to the financial results




Notes:-

1. The results of the quarter ended 30th June ,2023 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11th August, 2023. The statutory auditors of the Company carried out a "Limited Review" of the financial results for quarter ended 30th June ,2023.

2. Other Financial indicators

(Rs. in Lakhs)

Particulars	3 months	3 months	3 months	12 months
	ended 30/06/2023	ended 31/03/2023	ended 30/06/2022	ended 31/03/2023
EBITDA	1,744.49	1,527.08	1,213.96	5,738.91
% of EBITDA Margin	10.80	9.71	10.43	10.88
EBITDA (Adjusted to Forex (gain) / loss and Mark to Market (gain) / loss on Investment in Mutual funds)	1,472.61	1,494.90	1,277.80	5,630.55
% of Adjusted EBITDA Margin	9.12	9.50	10.98	10.67

3. The figures for the quarter ended 31st March, 2023 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto the third quarter of the relevant financial year.

4. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

5. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Ltd.



Ritesh Shah
Joint Managing Director
(DIN: 02496729)



Place : Mumbai

Date : 11th August, 2023